Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Anti-CD19/BCMA CAR T-cells(Shanghai Xiniao Biotechnology) in Myositis: NCT06941129 Clinical Landscape Report 2026
15 October 2026
NCT06941129 clinical landscape for Myositis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tebentafusp in Clear Cell Sarcoma: NCT06942442 Clinical Landscape Report 2026
15 October 2026
NCT06942442 clinical landscape for Clear Cell Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axicabtagene Ciloleucel in Large B-cell lymphoma: NCT06935136 Clinical Landscape Report 2026
15 October 2026
NCT06935136 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IOV-3001 in Uveal Melanoma: NCT06940739 Clinical Landscape Report 2026
15 October 2026
NCT06940739 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ivonescimab in Renal Cell Carcinoma: NCT06940518 Clinical Landscape Report 2026
15 October 2026
NCT06940518 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MT-4561 in Endometrial Carcinoma: NCT06943521 Clinical Landscape Report 2026
15 October 2026
NCT06943521 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Amlodipine Besylate in Endometrial Carcinoma: NCT06942377 Clinical Landscape Report 2026
15 October 2026
NCT06942377 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NY-ESO-1 Targeted TCR-T (Fanen Bio) in Sarcoma: NCT06942143 Clinical Landscape Report 2026
15 October 2026
NCT06942143 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GB-261 in Systemic Lupus Erythematosus: NCT06945068 Clinical Landscape Report 2026
15 October 2026
NCT06945068 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
YTS-109 in Purpura, Thrombocytopenic, Idiopathic: NCT06943937 Clinical Landscape Report 2026
15 October 2026
NCT06943937 clinical landscape for Purpura, Thrombocytopenic, Idiopathic: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
HS-IT101 in Uveal Melanoma: NCT06941818 Clinical Landscape Report 2026
15 October 2026
NCT06941818 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CHT-101 in Systemic Lupus Erythematosus: NCT06946485 Clinical Landscape Report 2026
15 October 2026
NCT06946485 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.